Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2018 · 10-Q
Revenue—
Net Income-$1.17M-$1.17MN/M vs Q1 2017 EPS Diluted$0.00$0.00N/M vs Q1 2017 Operating Income-$1,174,816N/M Operating Cash Flow-$1,131,687N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2018 · filed May 1, 2018 · 31 d after period end